NCT00514137 · OUTCOME

Toxicity

Sunitinib in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2014-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: From the time of first treatment to up to 30 days after the last day of study drug treatment

What was measured

Assessed per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Included are the toxicities at least possibly related to the study drug.

Groups in this outcome

Treatment (Kinase Inhibitor Therapy)

Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Kinase Inhibitor Therapy)	13

Reported measurements

Grade 3+ Adverse Events

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Kinase Inhibitor Therapy)	10	Not reported	Not reported	Not reported	Not reported

Grade 4+ Adverse Events

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Kinase Inhibitor Therapy)	3	Not reported	Not reported	Not reported	Not reported

Grade 5 Adverse Events

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Kinase Inhibitor Therapy)	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
10
title
Grade 3+ Adverse Events
categories
measurements
group Id
OG000
value
3
title
Grade 4+ Adverse Events
categories
measurements
group Id
OG000
value
0
title
Grade 5 Adverse Events

denoms

counts
group Id
OG000
value
13
units
Participants

description

Assessed per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Included are the toxicities at least possibly related to the study drug.

groups

description
Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Treatment (Kinase Inhibitor Therapy)

param Type

NUMBER

reporting Status

POSTED

time Frame

From the time of first treatment to up to 30 days after the last day of study drug treatment

title

Toxicity

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice